Mary Glindon Alert Sample


Alert Sample

View the Parallel Parliament page for Mary Glindon

Information between 15th April 2024 - 5th May 2024

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.


Division Votes
24 Apr 2024 - Renters (Reform) Bill - View Vote Context
Mary Glindon voted Aye - in line with the party majority and against the House
One of 136 Labour Aye votes vs 0 Labour No votes
Tally: Ayes - 158 Noes - 282
24 Apr 2024 - Renters (Reform) Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 133 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 283 Noes - 143
24 Apr 2024 - Renters (Reform) Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 136 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 287 Noes - 144
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon was Teller for the Noes and against the House
Tally: Ayes - 312 Noes - 237
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 164 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 304 Noes - 222
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon was Teller for the Noes and against the House
Tally: Ayes - 305 Noes - 234
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon was Teller for the Noes and against the House
Tally: Ayes - 306 Noes - 229
17 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon was Teller for the Noes and against the House
Tally: Ayes - 302 Noes - 244
17 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon was Teller for the Noes and against the House
Tally: Ayes - 310 Noes - 240
17 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon was Teller for the Noes and against the House
Tally: Ayes - 306 Noes - 240
17 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mary Glindon was Teller for the Noes and against the House
Tally: Ayes - 306 Noes - 240
16 Apr 2024 - Tobacco and Vapes Bill - View Vote Context
Mary Glindon voted Aye - in line with the party majority and in line with the House
One of 161 Labour Aye votes vs 0 Labour No votes
Tally: Ayes - 383 Noes - 67
30 Apr 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 99 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 273 Noes - 163
30 Apr 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 103 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 272 Noes - 162
30 Apr 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 102 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 274 Noes - 162
30 Apr 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 102 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 276 Noes - 161
30 Apr 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Mary Glindon voted No - in line with the party majority and against the House
One of 102 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 273 Noes - 159


Speeches
Mary Glindon speeches from: Tobacco and Vapes Bill (Third sitting)
Mary Glindon contributed 1 speech (347 words)
Committee stage:s: 3rd sitting
Wednesday 1st May 2024 - Public Bill Committees
Department of Health and Social Care
Mary Glindon speeches from: Tobacco and Vapes Bill (First sitting)
Mary Glindon contributed 1 speech (24 words)
Committee stage: 1st sitting
Tuesday 30th April 2024 - Public Bill Committees
Department of Health and Social Care
Mary Glindon speeches from: Tobacco and Vapes Bill (Second sitting)
Mary Glindon contributed 4 speeches (1,055 words)
Committee stage: 2nd sitting
Tuesday 30th April 2024 - Public Bill Committees
Department of Health and Social Care
Mary Glindon speeches from: High Streets (Designation, Review and Improvement Plan) Bill
Mary Glindon contributed 2 speeches (1,293 words)
3rd reading
Friday 26th April 2024 - Commons Chamber
Department for Levelling Up, Housing & Communities
Mary Glindon speeches from: Business of the House
Mary Glindon contributed 1 speech (85 words)
Thursday 25th April 2024 - Commons Chamber
Leader of the House
Mary Glindon speeches from: Oral Answers to Questions
Mary Glindon contributed 1 speech (53 words)
Wednesday 24th April 2024 - Commons Chamber
Cabinet Office
Mary Glindon speeches from: International Freedom of Religion or Belief Bill
Mary Glindon contributed 1 speech (351 words)
Committee stage
Wednesday 24th April 2024 - Public Bill Committees
Mary Glindon speeches from: Oral Answers to Questions
Mary Glindon contributed 2 speeches (103 words)
Thursday 18th April 2024 - Commons Chamber
Department for Digital, Culture, Media & Sport
Mary Glindon speeches from: Finance (No. 2) Bill
Mary Glindon contributed 1 speech (59 words)
2nd reading
Wednesday 17th April 2024 - Commons Chamber
HM Treasury
Mary Glindon speeches from: Oral Answers to Questions
Mary Glindon contributed 2 speeches (91 words)
Tuesday 16th April 2024 - Commons Chamber
Department for Energy Security & Net Zero
Mary Glindon speeches from: Tobacco and Vapes Bill
Mary Glindon contributed 1 speech (761 words)
2nd reading
Tuesday 16th April 2024 - Commons Chamber
Department of Health and Social Care
Mary Glindon speeches from: Oral Answers to Questions
Mary Glindon contributed 2 speeches (79 words)
Monday 15th April 2024 - Commons Chamber
Home Office


Written Answers
NHS: Staff
Asked by: Mary Glindon (Labour - North Tyneside)
Monday 15th April 2024

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when she plans to publish further information on the implementation of the NHS long-term workforce plan.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

We have established a Long Term Workforce Plan Governance Board which will ensure the delivery and review the progress of the Long Term Workforce Plan’s implementation. The modelling NHS England has used in the plan is founded on data, evidence, and analysis and provides a set of broad ranges to measure the potential impact of actions over its 15 year timeframe. We have committed to refreshing the modelling that underpins the plan every two years, or in line with fiscal events.

Parkinson's Disease: Health Services
Asked by: Mary Glindon (Labour - North Tyneside)
Monday 15th April 2024

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will amend the NHS long-term workforce plan to help tackle regional variations in access to Parkinson’s specialist care.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The NHS Long Term Workforce Plan (LTWP) sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years. It covers the majority of NHS workforce groups, including those working on Parkinson’s disease. The LTWP commits to working closely with systems to consider the best approaches to reviewing the geographical distribution of training posts for wider professional groups.

Social Security Benefits: Parkinson's Disease
Asked by: Mary Glindon (Labour - North Tyneside)
Tuesday 16th April 2024

Question to the Department for Work and Pensions:

To ask the Secretary of State for Work and Pensions, if he will hold discussions with (a) the hon. Member for North Tyneside and (b) Parkinson's UK on the potential impact of the social security system on people living with Parkinson's disease.

Answered by Mims Davies - Minister of State (Department for Work and Pensions)

The Work Capability Assessment (WCA) assesses individuals against a set of descriptors to determine how their health condition or disability affects their ability to work. The WCA takes into account the functional effects of fluctuating and degenerative conditions such as Parkinson’s. A key principle is that the WCA considers the impact that a person’s disability or health condition has on them, not the condition itself.

Claimants with the most severe health conditions and disabilities whose condition is unlikely to ever improve are no longer routinely reassessed.

From 2025, we are reforming the WCA to reflect new flexibilities in the labour market and greater employment opportunities for disabled people and people with health conditions, whilst maintaining protections for those with the most significant conditions. Claimants who currently have no work-related requirements, except in some very limited circumstances, will not be reassessed or lose benefit because of these changes.

When making decisions on changes to the WCA, we carefully considered over 1300 consultation responses, including from disabled people, people with health conditions, and the organisations that represent and support them. We also engaged directly with clinical experts, employer groups and disability organisations across the country.

With these changes to the WCA criteria, 371,000 fewer people will be assessed as having limited capability for work and work-related activity by 2028-29 and will receive personalised support to help them move closer to employment. A further 29,000 individuals will be found fit for work by 2028-29 and will receive more intensive support to search for and secure work than would be the case under the current WCA rules. These figures are not based on specific conditions. This is because the WCA considers the impact that a person’s disability or health condition has on their ability to work, not the condition itself.

The department routinely engages with a wide range of organisations that represent and support disabled people and people with health conditions, including people living with Parkinson’s disease.

Work Capability Assessment: Parkinson's Disease
Asked by: Mary Glindon (Labour - North Tyneside)
Tuesday 16th April 2024

Question to the Department for Work and Pensions:

To ask the Secretary of State for Work and Pensions, if he will make an assessment of the potential impact of proposed changes to Work Capability Assessments on people with Parkinson's disease.

Answered by Mims Davies - Minister of State (Department for Work and Pensions)

The Work Capability Assessment (WCA) assesses individuals against a set of descriptors to determine how their health condition or disability affects their ability to work. The WCA takes into account the functional effects of fluctuating and degenerative conditions such as Parkinson’s. A key principle is that the WCA considers the impact that a person’s disability or health condition has on them, not the condition itself.

Claimants with the most severe health conditions and disabilities whose condition is unlikely to ever improve are no longer routinely reassessed.

From 2025, we are reforming the WCA to reflect new flexibilities in the labour market and greater employment opportunities for disabled people and people with health conditions, whilst maintaining protections for those with the most significant conditions. Claimants who currently have no work-related requirements, except in some very limited circumstances, will not be reassessed or lose benefit because of these changes.

When making decisions on changes to the WCA, we carefully considered over 1300 consultation responses, including from disabled people, people with health conditions, and the organisations that represent and support them. We also engaged directly with clinical experts, employer groups and disability organisations across the country.

With these changes to the WCA criteria, 371,000 fewer people will be assessed as having limited capability for work and work-related activity by 2028-29 and will receive personalised support to help them move closer to employment. A further 29,000 individuals will be found fit for work by 2028-29 and will receive more intensive support to search for and secure work than would be the case under the current WCA rules. These figures are not based on specific conditions. This is because the WCA considers the impact that a person’s disability or health condition has on their ability to work, not the condition itself.

The department routinely engages with a wide range of organisations that represent and support disabled people and people with health conditions, including people living with Parkinson’s disease.

Dementia and Parkinson's Disease: Health Services and Social Services
Asked by: Mary Glindon (Labour - North Tyneside)
Tuesday 23rd April 2024

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to provide training in Parkinson’s-related dementia care for health and social care professionals.

Answered by Helen Whately - Minister of State (Department of Health and Social Care)

The standard of training for health care professionals is the responsibility of the health care independent statutory regulatory bodies. They set the outcome standards expected at undergraduate level and approve courses and Higher Education Institutions to write and teach the curricula content that enables their students to meet the regulators outcome standards.

Whilst not all curricula may necessarily highlight a specific condition, they all nevertheless emphasize the skills and approaches a health care practitioner must develop in order to ensure accurate and timely diagnoses and treatment plans for their patients, including for dementia.

Individual employers across health and social care are responsible for ensuring their staff are trained and competent to carry out their role, and for investing in the future of their staff by providing continuing professional development (CPD) funding. The required training needs are set out in the Dementia Training Standards Framework, which is available at the following link:

https://www.skillsforhealth.org.uk/info-hub/dementia-2015-updated-2018/

The framework was commissioned and funded by the Department, and developed in collaboration with the sector. It sets out the essential knowledge, skills, and expected learning outcomes applicable across the health and care spectrum.

It is applicable to health and social care staff who work with people living with dementia, staff providing direct care and support, and those who provide leadership in transforming care, including social care managers and leaders.

To supplement local National Health Service employer investment for CPD, the NHS Long Term Workforce Plan, published on 30 June 2023, sets out NHS England’s commitment to continue national CPD funding for nurses, midwives, and allied health professionals. There are a variety of resources available on the NHS England e-learning for health platform, designed to enhance the training and education of the health and social care workforce. This includes a programme on dementia care, and modules in Parkinson’s disease in geriatric medicine.




Mary Glindon mentioned

Parliamentary Debates
High Streets (Designation, Review and Improvement Plan) Bill
24 speeches (14,511 words)
3rd reading
Friday 26th April 2024 - Commons Chamber
Department for Levelling Up, Housing & Communities
Mentions:
1: Maria Miller (Con - Basingstoke) Member for North Tyneside (Mary Glindon) said, they are places where we gather. - Link to Speech
2: Justin Madders (Lab - Ellesmere Port and Neston) Friend the Member for North Tyneside (Mary Glindon) gave us a glowing gallop through her part of the - Link to Speech
3: Jacob Young (Con - Redcar) Member for North Tyneside (Mary Glindon), was named in honour of the world war two hero who retrieved - Link to Speech
4: Jack Brereton (Con - Stoke-on-Trent South) Member for North Tyneside (Mary Glindon), who referred to the impact of the transforming cities fund - Link to Speech

Renters (Reform) Bill
107 speeches (34,972 words)
Report stage
Wednesday 24th April 2024 - Commons Chamber
Department for Levelling Up, Housing & Communities
Mentions:
1: Matthew Pennycook (Lab - Greenwich and Woolwich) Friends the Members for Weaver Vale (Mike Amesbury), for Westminster North (Ms Buck), for North Tyneside (Mary - Link to Speech

Tobacco and Vapes Bill
213 speeches (48,358 words)
2nd reading
Tuesday 16th April 2024 - Commons Chamber
Department of Health and Social Care
Mentions:
1: Preet Kaur Gill (LAB - Birmingham, Edgbaston) Friends the Members for North Tyneside (Mary Glindon), for York Central, (Rachael Maskell) and for Dulwich - Link to Speech




Mary Glindon - Select Committee Information

Calendar
Wednesday 24th April 2024 10 a.m.
International Freedom of Religion or Belief Bill - Debate
Subject: To consider the Bill
View calendar
Wednesday 24th April 2024 10 a.m.
International Freedom of Religion or Belief Bill - Debate
Subject: To consider the Bill
View calendar
Tuesday 30th April 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: To consider the Bill
View calendar
Tuesday 30th April 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: To consider the Bill
View calendar
Tuesday 30th April 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
View calendar
Tuesday 30th April 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
View calendar
Wednesday 1st May 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
View calendar
Wednesday 1st May 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
View calendar
Wednesday 1st May 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 9:25am: Oral evidence
Professor Sir Chris Whitty, Chief Medical Officer for England
Sir Francis Atherton, Chief Medical Officer for Wales
Professor Sir Michael McBride, Chief Medical Officer for Northern Ireland
Professor Sir Gregor Ian Smith, Chief Medical Officer for Scotland
At 10:25am: Oral evidence
Professor Sir Steven Powis - National Medical Director at NHS England
Kate Brintworth - Chief Midwifery Officer at NHS England
At 10:55am: Oral evidence
Professor Kamilla Hawthorne MBE - Chair of the Council at Royal College of General Practitioners
Professor Steve Turner - President at Royal College of Paediatrics and Child Health (RCPCH)
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
Dr Allison Ford - Associate Professor at University of Stirling
At 4:25pm: Oral evidence
Professor Robert West - Professor Emeritus of Health Psychology at University College London
Professor Ann McNeill - Professor of Tobacco Addiction at Kings College London
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
Dr Allison Ford - Associate Professor at University of Stirling
At 4:25pm: Oral evidence
Professor Robert West - Professor Emeritus of Health Psychology at University College London
Professor Ann McNeill - Professor of Tobacco Addiction at Kings College London
View calendar
Wednesday 1st May 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 9:25am: Oral evidence
Professor Sir Chris Whitty, Chief Medical Officer for England
Sir Francis Atherton, Chief Medical Officer for Wales
Professor Sir Michael McBride, Chief Medical Officer for Northern Ireland
Professor Sir Gregor Ian Smith, Chief Medical Officer for Scotland
At 10:25am: Oral evidence
Professor Sir Steven Powis - National Medical Director at NHS England
Kate Brintworth - Chief Midwifery Officer at NHS England
At 10:55am: Oral evidence
Professor Kamilla Hawthorne MBE - Chair of the Council at Royal College of General Practitioners
Professor Steve Turner - President at Royal College of Paediatrics and Child Health (RCPCH)
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Professor Allison Ford - Associate Professor at the Institute for Social Marketing and Health at University of Stirling
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Professor Allison Ford - Associate Professor at the Institute for Social Marketing and Health at University of Stirling
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Professor Allison Ford - Associate Professor at the Institute for Social Marketing and Health at University of Stirling
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Professor Allison Ford - Associate Professor at the Institute for Social Marketing and Health at University of Stirling
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
View calendar
Tuesday 30th April 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Cllr David Fothergill - Deputy Chair of the LGA, Chairman of the LGA Community Wellbeing Board at Local Government Association (LGA)
Greg Fell - President at Association of Directors of Public Health
At 2:30pm: Oral evidence
Ailsa Rutter OBE - Director at Fresh and Balance North East
At 2:50pm: Oral evidence
Adrian Simpson - Policy Adviser – Retail Products at British Retail Consortium
At 3:10pm: Oral evidence
John Herriman - CEO at Chartered Trading Standards Institute (CTSI)
Kate Pike - CTSI Lead Officer for Vaping at Chartered Trading Standards Institute (CTSI)
At 3:40pm: Oral evidence
Laura Young - PhD Student at Centre for Water Law, Policy and Science, University of Dundee
At 4:00pm: Oral evidence
Professor Linda Bauld OBE - Bruce and John Usher Chair in Public Health at University of Edinburgh
At 4:20pm: Oral evidence
Professor Robert West - Professor Emeritus of Health Psychology at University College London (UCL)
Professor Ann McNeill - Professor of Tobacco Addiction at King’s College London
View calendar
Tuesday 30th April 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Cllr David Fothergill - Deputy Chair of the LGA, Chairman of the LGA Community Wellbeing Board at Local Government Association (LGA)
Greg Fell - President at Association of Directors of Public Health
At 2:30pm: Oral evidence
Ailsa Rutter OBE - Director at Fresh and Balance North East
At 2:50pm: Oral evidence
Adrian Simpson - Policy Adviser – Retail Products at British Retail Consortium
At 3:10pm: Oral evidence
John Herriman - CEO at Chartered Trading Standards Institute (CTSI)
Kate Pike - CTSI Lead Officer for Vaping at Chartered Trading Standards Institute (CTSI)
At 3:40pm: Oral evidence
Laura Young - PhD Student at Centre for Water Law, Policy and Science, University of Dundee
At 4:00pm: Oral evidence
Professor Linda Bauld OBE - Bruce and John Usher Chair in Public Health at University of Edinburgh
At 4:20pm: Oral evidence
Professor Robert West - Professor Emeritus of Health Psychology at University College London (UCL)
Professor Ann McNeill - Professor of Tobacco Addiction at King’s College London
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
Dr Allison Ford - Associate Professor at University of Stirling
View calendar
Wednesday 1st May 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Professor Sanjay Agrawal - RCP’s special adviser on tobacco at Royal College of Physicians
Dr Tim Mitchell - President at Royal College of Surgeons
At 2:40pm: Oral evidence
Mark Rowland - Chief Executive at Mental Health Foundation
At 3:00pm: Oral evidence
Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA)
At 3:25pm: Oral evidence
Mr David Lawson - Director at Inter Scientific Ltd.
At 3:45pm: Oral evidence
Dr Rob Branston - Senior Lecturer at University of Bath
Professor Anna Gilmore - Professor of Public Health at University of Bath
Dr Allison Ford - Associate Professor at University of Stirling
View calendar
Tuesday 30th April 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Cllr David Fothergill - Deputy Chair of the LGA, Chairman of the LGA Community Wellbeing Board at Local Government Association (LGA)
Greg Fell - President at Association of Directors of Public Health
At 2:30pm: Oral evidence
Ailsa Rutter OBE - Director at Fresh and Balance North East
At 2:50pm: Oral evidence
Adrian Simpson - Policy Adviser – Retail Products at British Retail Consortium
At 3:10pm: Oral evidence
John Herriman - CEO at Chartered Trading Standards Institute (CTSI)
Kate Pike - CTSI Lead Officer for Vaping at Chartered Trading Standards Institute (CTSI)
At 3:40pm: Oral evidence
Laura Young - PhD Student at Centre for Water Law, Policy and Science, University of Dundee
View calendar
Tuesday 30th April 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: To consider the Bill
At 9:25am: Oral evidence
Michelle Mitchell OBE - Chief Executive at Cancer Research UK
Deborah Arnott - Chief Executive at Action on Smoking and Health (ASH)
Sheila Duffy - Chief Executive at Action on Smoking and Health Scotland
At 10:05am: Oral evidence
Dr Charmaine Griffiths - Chief Executive at British Heart Foundation
Sarah Sleet - Chief Executive Officer at Asthma and Lung UK
At 10:40am: Oral evidence
Dr Patrick Roach - General Secretary at NASUWT - The Teachers' Union
Matthew Shanks - Chair at Secondary Teacher Reference Group
At 11:10am: Oral evidence
Paul Farmer - Chief Executive at Age UK
View calendar
Tuesday 30th April 2024 2 p.m.
Tobacco and Vapes Bill - Oral evidence
Subject: Further to consider the Bill
At 2:00pm: Oral evidence
Cllr David Fothergill - Deputy Chair of the LGA, Chairman of the LGA Community Wellbeing Board at Local Government Association (LGA)
Greg Fell - President at Association of Directors of Public Health
At 2:30pm: Oral evidence
Ailsa Rutter OBE - Director at Fresh and Balance North East
At 2:50pm: Oral evidence
Adrian Simpson - Policy Adviser – Retail Products at British Retail Consortium
At 3:10pm: Oral evidence
John Herriman - CEO at Chartered Trading Standards Institute (CTSI)
Kate Pike - CTSI Lead Officer for Vaping at Chartered Trading Standards Institute (CTSI)
At 3:40pm: Oral evidence
Laura Young - PhD Student at Centre for Water Law, Policy and Science, University of Dundee
View calendar
Tuesday 30th April 2024 9:25 a.m.
Tobacco and Vapes Bill - Oral evidence
Subject: To consider the Bill
At 9:25am: Oral evidence
Michelle Mitchell OBE - Chief Executive at Cancer Research UK
Deborah Arnott - Chief Executive at Action on Smoking and Health (ASH)
Sheila Duffy - Chief Executive at Action on Smoking and Health Scotland
At 10:05am: Oral evidence
Dr Charmaine Griffiths - Chief Executive at British Heart Foundation
Sarah Sleet - Chief Executive Officer at Asthma and Lung UK
At 10:40am: Oral evidence
Dr Patrick Roach - General Secretary at NASUWT - The Teachers' Union
Matthew Shanks - Chair at Secondary Teacher Reference Group
At 11:10am: Oral evidence
Paul Farmer - Chief Executive at Age UK
View calendar
Thursday 9th May 2024 11:30 a.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Thursday 9th May 2024 2 p.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Thursday 9th May 2024 11:30 a.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Thursday 9th May 2024 2 p.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Thursday 16th May 2024 2 p.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Thursday 16th May 2024 11:30 a.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Thursday 16th May 2024 2 p.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Thursday 16th May 2024 11:30 a.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Tuesday 14th May 2024 2 p.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Tuesday 14th May 2024 9:25 a.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Tuesday 14th May 2024 2 p.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar
Tuesday 14th May 2024 9:25 a.m.
Tobacco and Vapes Bill - Debate
Subject: Further to consider the Bill
View calendar